Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
$6.20
-$0.47(-4.69%)
At close: 4:00 PM EST
$6.20
-$0.47(-4.69%)
Day’s Range― - ―
52-Week Range$4.81 - $13.88
Previous Close$9.5
Volume184.55K
Average Volume (3M)710.17K
Market Cap
$1.40M
Enterprise ValueN/A
Total Cash (Recent Filing)$136.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 17, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,590,025
10 Day Avg. Volume748,848
30 Day Avg. Volume710,171
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$86.33Price Target Upside1292.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCYB004 approaching a key inflection point, with completed enrollment in the Phase 2a trial in generalized anxiety disorder positioning the upcoming readout as a catalyst that could reshape investor perception of DMT programs.
Market PositionCYB003 pivotal program scaling globally, with ongoing preparations in commercial-scale manufacturing and clinic partnerships advancing in parallel, setting up CYB003 as a potential first-in-class intermittent treatment for major depressive disorder.
Regulatory ApprovalsCYB003 Phase 3 EMBRACE trial regulatory clearances underscore scale and speed of execution, with approvals secured in the U.K. and selected EU territories.
Bears Say
Market TimingCYBN expects to report top-line data from the first Phase 3 trial for CYB003 in major depressive disorder in the second half of 2026.
Valuation ConcernsCYBN still does not ascribe any value for CYB004 for generalized anxiety disorder in the valuation, viewing the product as not reflected in the stock in any appreciable way.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $13.88 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.40M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Nov 17, 2025 which is in 31 days.
How were Cybin’s earnings last quarter?
Currently, no data Available
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.95.
How many shares outstanding does Cybin have?
Cybin has 23,590,025 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Stock 12 Month Forecast
Average Price Target
$86.33
▲(1292.42% Upside)